General MM,   Patients non-eligible for transplant,  Relapsed/refractory patients,   & 1 more

ASH 2018 | Practice changing abstracts in multiple myeloma

Did you miss ASH 2018? The Multiple Myeloma Hub attended the 60th ASH Annual Meeting & Exposition, December 1–4 2018, San Diego, CA and has developed a downloadable resource, which provides information on the practice changing abstracts across multiple myeloma (MM).

Our selection of ASH abstracts includes comments from the MM Hub Steering Committee on the key phase III clinical trials presented during ASH, such as TOURMALINE-MM3 and Alycone, as well as the results from the pivotal study of selinexor with dexamethasone in penta-refractory MM and the first reports on the effect of melflufen treatment on progression free survival.

ASH 2018 | Practice changing abstracts in multiple myeloma

If you would like to view the ASH 2018 highlights, practice changing abstracts and expert opinions please find the Multiple Myeloma Hub resource below

Download Here
References
  1. #301: Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

    https://multiplemyelomahub.com/medical-information/ash-2018-ixazomib-maintenance-for-patients-with-newly-diagnosed-multiple-myeloma-results-from-the-tourmaline-mm3-trial
  2. #126: VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

    https://multiplemyelomahub.com/medical-information/long-term-follow-up-of-the-gem05menos65-clinical-trial-for-newly-diagnosed-multiple-myeloma
  3. #156: One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone

    https://ash.confex.com/ash/2018/webprogram/Paper113183.html
  4. #LBA-2: Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

    https://multiplemyelomahub.com/medical-information/daratumumab-triplet-regimen-as-a-frontline-treatment-for-multiple-myeloma-patients-non-eligible-for-asct-interim-results-of-the-maia-trial 
  5. #598: Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta Exposed and Triple Class-Refractory MM

    https://ash.confex.com/ash/2018/webprogram/Paper116663.html
  6. #600 OP-106: Horizon - Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS

    https://ash.confex.com/ash/2018/webprogram/Paper113095.html
Was this article informative? Thank you for your feedback!